We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

80 hedge funds and large institutions have $113M invested in Lineage Cell Therapeutics in 2015 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

508% more call options, than puts

Call options by funds: $3.08M | Put options by funds: $507K

240% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 5

42% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 19

16% more funds holding

Funds holding: 69 → 80 (+11)

0.72% more ownership

Funds ownership: 45.54% → 46.25% (+0.72%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

26% less capital invested

Capital invested by funds: $152M → $113M (-$38.9M)

Holders
80
Holders Change
+11
Holders Change %
+15.94%
% of All Funds
2.16%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
17
Increased
27
Reduced
19
Closed
5
Calls
$3.08M
Puts
$507K
Net Calls
+$2.58M
Net Calls Change
+$478K

Top Buyers

1
DWM
Destination Wealth Management
California
+$2.85M
2
TC
TFS Capital
Pennsylvania
+$1.24M
3
Renaissance Technologies
Renaissance Technologies
New York
+$793K
4
OAM
Oxford Asset Management
United Kingdom
+$544K
5
VKH
Virtu KCG Holdings
New York
+$385K

Top Sellers

1
CCM
Consonance Capital Management
New York
-$4.55M
2
CC
CQS Cayman
Cayman Islands
-$683K
3
MHP
Manatuck Hill Partners
Connecticut
-$623K
4
Citadel Advisors
Citadel Advisors
Florida
-$363K
5
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
-$223K
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
26
Pointe Capital Management
Michigan
$284K – – –
TA
27
Teachers Advisors
New York
$266K +$12.7K +3,269 +4%
PNC Financial Services Group
28
PNC Financial Services Group
Pennsylvania
$254K – – –
Group One Trading
29
Group One Trading
Illinois
$236K +$174K +44,858 +126%
Two Sigma Investments
30
Two Sigma Investments
New York
$232K +$307K +79,122 New
Millennium Management
31
Millennium Management
New York
$229K +$303K +78,174 New
California Public Employees Retirement System
32
California Public Employees Retirement System
California
$215K – – –
WJA
33
Williams Jones & Associates
New York
$201K +$2.16K +557 +0.8%
New York State Common Retirement Fund
34
New York State Common Retirement Fund
New York
$201K +$266K +68,667 New
AllianceBernstein
35
AllianceBernstein
Tennessee
$179K +$37K +9,540 +19%
Bank of America
36
Bank of America
North Carolina
$179K +$75.9K +19,586 +47%
Goldman Sachs
37
Goldman Sachs
New York
$160K +$146K +37,720 +224%
Swiss National Bank
38
Swiss National Bank
Switzerland
$160K +$211K +54,517 New
AQR Capital Management
39
AQR Capital Management
Connecticut
$157K +$208K +53,644 New
BA
40
BlackRock Advisors
Delaware
$142K +$19K +4,910 +11%
D.E. Shaw & Co
41
D.E. Shaw & Co
New York
$141K +$5.92K +1,528 +3%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$131K -$19.5K -5,037 -10%
NFA
43
Nationwide Fund Advisors
Ohio
$122K -$21.9K -5,638 -12%
AIG
44
American International Group
New York
$112K -$20.2K -5,210 -12%
Susquehanna International Group
45
Susquehanna International Group
Pennsylvania
$106K -$65.3K -16,840 -32%
Wells Fargo
46
Wells Fargo
California
$96K +$97.8K +25,224 +333%
AFG
47
Albion Financial Group
Utah
$84K – – –
State Board of Administration of Florida Retirement System
48
State Board of Administration of Florida Retirement System
Florida
$83K – – –
Barclays
49
Barclays
United Kingdom
$73K -$121K -31,096 -51%
GC
50
Guggenheim Capital
Illinois
$65K -$1.1K -283 -1%
1
2
3 4

LCTX Hedge Fund Activity: Q2 2015 in Review

80 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2015, worth a combined $113M — down 26% from $152M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new LCTX positions and 5 closed out — a net gain of 12 holders — while 27 added to existing stakes and 19 trimmed.

The largest buyer was Destination Wealth Management, opening a new position worth an estimated $2.85M. The largest seller was Consonance Capital Management, cutting an estimated $4.55M.

  • 80 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2015, up from 69 in Q1 2015.
  • Funds reported $113M of Lineage Cell Therapeutics stock for Q2 2015, down 26% quarter-over-quarter.
  • 17 funds opened new Lineage Cell Therapeutics positions in Q2 2015 and 5 closed out, a net change of +12 holders.
  • The largest Lineage Cell Therapeutics buyer in Q2 2015 was Destination Wealth Management, an estimated $2.85M added.
  • The largest Lineage Cell Therapeutics seller in Q2 2015 was Consonance Capital Management, an estimated $4.55M sold.

Based on aggregated 13F filings for Q2 2015.